Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
transdermal drug delivery
Pharma
Love Pharma moves to buy transdermal opioid-use disorder player
Love signed a letter of intent to buy Naltrexone Therapeutics for IP covering the administration of a treatment of alcohol and opioid-use disorder.
Nick Paul Taylor
Oct 18, 2022 9:20am
Zosano suspends migraine patch program after FDA knockback
May 3, 2022 1:34pm
Moffitt Dyves back into tumor pH modulation
Feb 7, 2022 7:40am
Kyowa sells rights to cancer drug delivery patch to Cumberland
Jan 11, 2022 9:30am
Corium snags PDUFA date for weekly Alzheimer's patch
Oct 19, 2021 7:25am
FDA shares advice on bioequivalence of different dosage forms
Aug 24, 2021 7:45am
